• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Maintain competitive cost structure in uncertain economic times

Article

Regardless of an insurer's composition - public or private, large or small, geographically diverse or regionally focused - reducing non-labor general and administrative (G&A) expenses can contribute greatly to margin improvement.

Regardless of an insurer's composition - public or private, large or small, geographically diverse or regionally focused - reducing non-labor general and administrative (G&A) expenses can contribute greatly to margin improvement. While administrative costs constitute a much smaller percentage of total expenses than medical costs, by improving the G&A ratio by 0.5%, an organization can accomplish the same impact to EBITDA as a 10% increase in membership.

The G&A ratio is commonly used to compare payers to their peers in the market. However, when used alone, it can be misleading or can be used to substantiate market standing. For example, when payers are above their peer average ratio, the natural tendency is to make rationalizations to defend their position. Conversely, when payers are below the average, the comparison can be a comforting indication that the organization is doing well. This, in turn, can lead to complacency or a suboptimal prioritization of improvement opportunities. Ratios and other comparative tools are a great starting point for self-evaluation.

While ratios and aggregate level information can be useful, the best way to determine opportunities for improvement is to let a payer's specific situation dictate whether costs can be reduced. If a payer needs to be more competitive in the market, either due to increased competition or to offset rising costs, then that factor alone should be driving opportunities.

When evaluating and prioritizing cost reduction opportunities, several clues indicate where cost reduction opportunities exist. Payers can classify these signals as high level or detailed account observations.

High level observations:

Gather these observations through internet research, discussions with sales representatives, meetings with industry peers, and finance reports. General questions include:

Detailed account observations

High performing organizations typically have this information available for analysis.

After a payer completes a high level and detailed analysis, the answers can serve as the basis for supporting savings targets. However, a payer also must balance the business case findings with the specific requirements of the organization. For example, if a payer needs to be more competitive in the market, due to increased competition or to offset rising costs, then that factor should be incorporated into the savings targets and strategy.

Related Videos
Video 6 - "Navigating Insurance Coverage for Prescription Digital Therapeutics"
Video 5 - "FDA Approval Pathway for Prescription Digital Therapeutics"
Video 8 - "Gaps in Evidence Generation for Digital Therapeutics"
Video 7 - "Adoption Lessons For Payers"
Video 10 - "Managing Self Care"
Video 3 - "Embracing and Improving Access to Technology Tools"
Video 4 - "Assessing the Cost-Effectiveness of Prescription Digital Therapeutics "
© 2024 MJH Life Sciences

All rights reserved.